Literature DB >> 5402543

Experimental "in vivo" studies of new antituberculosis drugs: capreomycin, ethambutol, rifampicin.

F Grumbach.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1969        PMID: 5402543

Source DB:  PubMed          Journal:  Tubercle        ISSN: 0041-3879


× No keyword cloud information.
  7 in total

Review 1.  [Results of chemotherapy in tuberculosis].

Authors:  E Jancik
Journal:  Pneumonologie       Date:  1971

2.  [New paths of chemotherapy].

Authors:  G Urbanczik
Journal:  Pneumonologie       Date:  1971

Review 3.  Rifampicin: a review.

Authors: 
Journal:  Drugs       Date:  1971       Impact factor: 9.546

4.  Which aminoglycoside or fluoroquinolone is more active against Mycobacterium tuberculosis in mice?

Authors:  N Lounis; B Ji; C Truffot-Pernot; J Grosset
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

5.  Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against Mycobacterium tuberculosis.

Authors:  Mary A De Groote; Janet C Gilliland; Colby L Wells; Elizabeth J Brooks; Lisa K Woolhiser; Veronica Gruppo; Charles A Peloquin; Ian M Orme; Anne J Lenaerts
Journal:  Antimicrob Agents Chemother       Date:  2010-12-06       Impact factor: 5.191

6.  Sparfloxacin, ethambutol, and cortisol receptor inhibitor RU-40 555 treatment for disseminated Mycobacterium avium complex infection of normal C57BL/6 mice.

Authors:  C Perronne; Y Cohen; C Truffot-Pernot; J Grosset; J L Vildé; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

7.  Evaluation of high-dose rifampin in patients with new, smear-positive tuberculosis (HIRIF): study protocol for a randomized controlled trial.

Authors:  Meredith Milstein; Leonid Lecca; Charles Peloquin; Denis Mitchison; Kwonjune Seung; Marcello Pagano; David Coleman; Elna Osso; Julia Coit; Dante Elmo Vargas Vasquez; Epifanio Sanchez Garavito; Roger Calderon; Carmen Contreras; Geraint Davies; Carole D Mitnick
Journal:  BMC Infect Dis       Date:  2016-08-27       Impact factor: 3.090

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.